# EDGAR Filing Document

**Accession Number:** 0001860657
**File Stem:** 0001437749-25-020652
**Filing Date:** 2025-6
**Character Count:** 7221
**Document Hash:** 431d56534e1f2699d4494efcc152b43b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-020652.hdr.sgml**: 20250617

**ACCESSION NUMBER**: 0001437749-25-020652

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250613

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250617

**DATE AS OF CHANGE**: 20250617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Allarity Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001860657
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41160
- **FILM NUMBER:** 251053578

**BUSINESS ADDRESS:**
- **STREET 1:** 24 SCHOOL ST., 2ND FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108
- **BUSINESS PHONE:** 401-426-4664

**MAIL ADDRESS:**
- **STREET 1:** 24 SCHOOL ST., 2ND FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108

?xml version='1.0' encoding='ASCII'? allr20250617_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

__________________________________________________

**FORM 8-K**

__________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **June 13, 2025**

**ALLARITY THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41160** | **87-2147982** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| |
|:---|
| **123 E Tarpon Ave,**<br> **Tarpon Springs, FL 34689** |
| (Address of principal executive offices) |

---

**<u>(401) 426-4664</u>**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | ALLR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 13, 2025, Allarity Therapeutics, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, five proposals were submitted to the Company's stockholders of record for a vote. These proposals are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 30, 2025 (the "Proxy Statement"). At the Annual Meeting, a total of 6,986,031 (or 41%) of the Company's issued and outstanding shares of common stock held of record as of April 16, 2025, the record date for the Annual Meeting, were present either in person or by proxy, which constituted a quorum.

All proposals were approved by the requisite stockholder vote, except for the 2021 Plan Amendment Proposal and the Officer Exculpation Amendment Proposal. Although sufficient votes were received to approve the Adjournment Proposal, an adjournment was not necessary.

The final voting results for each proposal are set forth below. For additional information regarding the proposals, please refer to the Proxy Statement.

**Proposal 1**: To elect one (1) Class III director, Thomas H. Jensen, to serve until the 2028 annual meeting of stockholders or until his respective successor is duly elected and qualified (the "Director Proposal").

---

| | | | |
|:---|:---|:---|:---|
| *Nominee* | *For* | *Withheld* | *Broker Non-Votes* |
| Thomas H. Jensen | 1,673,698 | 265,465 | 5,046,868 |

---

**Proposal 2**: To ratify the appointment of Wolf & Company, P.C., as our independent registered public accounting firm for the fiscal year ending December 31, 2025 (the "Independent Auditor Proposal").

---

| | | | |
|:---|:---|:---|:---|
| *For* | *Against* | *Abstentions* | *Broker Non-Votes* |
| 6,706,148 | 239,253 | 40,630 | N/A |

---

**Proposal 3:** To approve an amendment to our Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan"), in substantially the form attached to the Proxy Statement as Appendix C, to increase the aggregate number of shares of Common Stock authorized for grant under the 2021 Plan from 717,941 to 3,415,068 (the "2021 Plan Amendment Proposal").

---

| | | | |
|:---|:---|:---|:---|
| *For* | *Against* | *Abstentions* | *Broker Non-Votes* |
| 928,978 | 932,866 | 77,319 | 5,046,868 |

---

**Proposal 4:** To approve an amendment to our Certificate of Incorporation, in substantially the form attached to the Proxy Statement as Appendix D, to limit the liability of certain officers as permitted by Delaware Law (the "Officer Exculpation Amendment Proposal").

---

| | | | |
|:---|:---|:---|:---|
| *For* | *Against* | *Abstentions* | *Broker Non-Votes* |
| 1,359,331 | 563,585 | 16,247 | 5,046,868 |

---

**Proposal 5:** To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Director Proposal, the Independent Auditor Proposal, the Share Decrease Proposal, the Reverse Stock Split Proposal, the 2021 Plan Amendment Proposal or the Officer Exculpations Amendment Proposal (the "Adjournment Proposal").

---

| | | | |
|:---|:---|:---|:---|
| *For* | *Against* | *Abstentions* | *Broker Non-Votes* |
| 4,976,159 | 1,924,694 | 85,178 | 5,046,868 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Allarity Therapeutics, Inc.** | **Allarity Therapeutics, Inc.** |
| Date: June 17, 2025 | By: | /s/ Thomas H. Jensen |
|  |  | Thomas H. Jensen |
|  |  | Chief Executive Officer  |

---